News and Notes


	General Information
	Infectious Disease
	Cancer
	Topical Microbicides
	Immune Modulation and Inflammation


	April 4th 2008: ImQuest scientists present important HIV Microbicide results at Microbicides 2008 in Delhi, India.

	April 1st 2008: ImQuest publishes results of structure activity relationship study with pyrimidinedione HIV inhibitors.

	September 24th 2007: ImQuest Life Sciences announces the appointment of Robert Schooley, M.D. to its Scientific Advisory Board.

	September 21st 2007: ImQuest Life Sciences announces the appointment of David Ho, M.D. to its Scientific Advisory Board.

	September 20th 2007: ImQuest Life Sciences announces the appointment of Richard J. Whitley, M.D. as Chairman of its Scientific Advisory Board.

	April 25th 2007: ImQuest Life Sciences Receives Grant from International Partnership for Microbicides to Develop Novel Microbicide

	April 25th 2006: ImQuest Life Sciences Licenses Piperazine Series of Anti-Cancer Therapeutic Compounds from Samjin Pharmaceutical Co.

	December 31, 2008: ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410.
	December 10, 2008: ImQuest Presentations at International HIV Meeting Highlight Significant Progress in Their Therapeutic and Microbicide Development Programs.
	August 6, 2008: ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission.
	July 29, 2008: ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide.
	April 16, 2008: ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528.
	April 4th 2008: ImQuest scientists present important HIV Microbicide results at Microbicides 2008 in Delhi, India.
	April 1st 2008: ImQuest publishes results of structure activity relationship study with pyrimidinedione HIV inhibitors.
	September 24th 2007: ImQuest Life Sciences announces the appointment of Robert Schooley, M.D. to its Scientific Advisory Board.
	September 21st 2007: ImQuest Life Sciences announces the appointment of David Ho, M.D. to its Scientific Advisory Board.
	September 20th 2007: ImQuest Life Sciences announces the appointment of Richard J. Whitley, M.D. as Chairman of its Scientific Advisory Board.
	April 25th 2007:ImQuest Life Sciences Receives Grant from International Partnership for Microbicides to Develop Novel Microbicide.
	April 25th 2006: ImQuest Life Sciences Licenses Piperazine Series of Anti-Cancer Therapeutic Compounds from Samjin Pharmaceutical Co.
	April 17th 2006: ISIS Pharmaceuticals licenses anti-HIV drug to ImQuest Life Sciences.
	February 28th 2006: ImQuest Life Sciences Licenses Entire Series of Anti-HIV Therapeutic Compounds from Samjin Pharmaceutical Co.
	October 20th 2005: ImQuest Life Sciences and Samjin Pharmaceutical Co. Form Strategic Drug Development Alliance.


Infectious Disease
	IQP-0410 for HIV
	HBV Lead Discovery
Anti-Cancer Agents
	IQP-0303 for leukemia
	IQP-0304 for prostate cancer
Topical Microbicides
	IQP-0528
	IQP-0831
	IQP-1187